Is Hepatic Steatosis the Same as Fatty Liver?

Hepatic steatosis is the medical term for fatty liver. The two phrases describe the same thing: an abnormal buildup of fat inside liver cells. Doctors, radiologists, and pathologists use “hepatic steatosis” in clinical reports and imaging results, while “fatty liver” is the plain-language equivalent patients hear in conversation. The condition is formally diagnosed when fat accumulates in more than 5% of liver cells, a threshold that holds whether the finding comes from a biopsy slide or an imaging scan.¹ Beyond the naming question, though, there is a lot worth understanding about what fatty liver actually involves, what causes it, and why the medical world recently overhauled the entire vocabulary around it.

Two Names, One Condition

“Hepatic” means relating to the liver. “Steatosis” comes from the Greek word for fat. Put them together and you get “liver fat” dressed in Latin and Greek. Both terms describe pathologically elevated fat content in the liver and can result from many different underlying causes.² A healthy liver contains some fat, but once the amount crosses that 5% threshold, the organ is considered steatotic. If you see “hepatic steatosis” on an ultrasound report, it is telling you the same thing your doctor means when they say “you have a fatty liver.”

Where confusion sometimes creeps in is that “fatty liver disease” implies a broader clinical picture. The word “disease” signals that the fat accumulation is not just a snapshot finding but part of an ongoing process that may need monitoring or treatment. Still, the core observation, fat in the liver, is the same whether the report says “steatosis” or “fatty liver.”

Why the Entire Naming System Just Changed

For decades, doctors split fatty liver into two main buckets based on alcohol intake. If you drank heavily, it was alcoholic liver disease. If you did not, it was nonalcoholic fatty liver disease, or NAFLD. That framework was simple, but it had real problems. The name “nonalcoholic” defined the condition by what it was not, which felt stigmatizing and told patients nothing about what was actually driving their disease. It also drew an artificial line between alcohol-related and metabolic causes when, in practice, many people have both contributing at once.

In 2023, a large international panel of liver specialists reached consensus on a new naming system. The umbrella term is now “steatotic liver disease,” or SLD, which covers all causes of liver fat accumulation. What used to be called NAFLD is now “metabolic dysfunction-associated steatotic liver disease,” or MASLD, defined by the presence of hepatic steatosis plus at least one of five cardiometabolic risk factors such as elevated blood sugar, high blood pressure, or excess waist circumference.³ Alcohol-related liver disease remains its own category, and a new hybrid term, MetALD, captures people who fall on the continuum between metabolic and alcohol-related causes.⁴

If your doctor still says “NAFLD” or “fatty liver,” that is not wrong. The old terms have not vanished overnight, and many clinicians use them interchangeably with the new ones while guidelines catch up. But you will increasingly see MASLD in lab reports and medical literature. The underlying condition has not changed; only the label has.

The Alcohol Question Is Not as Clear-Cut as It Seems

The old NAFLD diagnosis hinged on a specific alcohol cutoff: roughly two standard drinks per day for men and one for women. Drink less than that, and your fatty liver was “nonalcoholic.” But research has complicated this neat dividing line. Even low levels of alcohol consumption can worsen liver injury in people who already have metabolic risk factors, and there is currently no data supporting a safe level of alcohol for someone with metabolic fatty liver disease.⁵ The new MetALD category was created partly to acknowledge this gray zone, where metabolic drivers and moderate alcohol intake overlap in ways the old system could not capture.

What Causes Fat to Build Up in the Liver

The liver processes fat constantly, pulling in fatty acids from the bloodstream and also manufacturing new fat through a process called de novo lipogenesis. When the inflow or production of fat outpaces what the liver can burn or export, the excess gets stored inside liver cells. Insulin resistance is a central driver. In people with fatty liver tied to metabolic dysfunction, the liver’s own fat-making machinery runs at roughly triple the rate seen in lean individuals. A study measuring the contribution of newly made fat to liver triglycerides found it accounted for about 38% in people with fatty liver, compared with 19% in those who were obese without the condition and 11% in lean participants.⁶ Elevated blood sugar and insulin levels both stimulate this fat production, creating a cycle that feeds itself.

Other routes to hepatic steatosis include heavy alcohol use, which shifts the liver’s metabolic priorities toward fat storage; certain medications such as corticosteroids, tamoxifen, and some antiretrovirals; rapid weight loss or starvation; and rare genetic conditions. The gut microbiome also appears to play a role: disruptions in the balance of gut bacteria have been linked to fatty liver, with research focusing on how bacterial byproducts that reach the liver through the portal vein can promote fat accumulation and inflammation.⁷

When Fat Alone Becomes Something Worse

Simple steatosis, meaning fat in the liver without significant inflammation or cell damage, is the most common and mildest form. Many people live with it for years without symptoms. The concern is progression. In some individuals, the liver’s capacity to safely store fat is overwhelmed, and toxic fat byproducts accumulate. This triggers a cascade of damage inside liver cells: mitochondria malfunction, stress responses flare, and an inflammatory reaction sets in. The wound-healing response that follows activates cells that lay down scar tissue, which over time can lead to fibrosis, cirrhosis, and eventually liver failure.⁸

This more advanced stage used to be called NASH (nonalcoholic steatohepatitis) and is now called MASH (metabolic dysfunction-associated steatohepatitis). The defining feature on a biopsy is ballooning of liver cells, a sign of direct cellular injury, alongside inflammation and often early scarring.⁹ Not everyone with a fatty liver progresses to this stage, but predicting who will is one of the hardest problems in liver medicine today.

How Doctors Detect and Grade It

Hepatic steatosis is graded by how much of the liver is affected. The most commonly used histological grading system runs from grade 0 (healthy, less than 5% fat) through grade 1 (mild, 5–33%), grade 2 (moderate, 34–66%), to grade 3 (severe, above 66%).¹⁰ Radiology-based grading using CT scans applies slightly different thresholds, classifying mild steatosis as a fat fraction of 5–15%, moderate as 15–25%, and severe as 25% or more.¹¹

MRI-based proton density fat fraction measurement is considered the most accurate noninvasive method for quantifying liver fat. A systematic review and meta-analysis found it achieved near-perfect accuracy for detecting any steatosis, and remained highly accurate for distinguishing moderate and severe grades.¹² Ultrasound is cheaper and more widely available, and newer ultrasound-based techniques have improved in accuracy, though they still fall slightly behind MRI for grading higher levels of fat.¹³ Transient elastography with controlled attenuation parameter, a technology often bundled into FibroScan devices, is widely used in clinical practice but shows lower accuracy at higher fat grades compared to MRI.¹⁴

Liver biopsy remains the reference standard for diagnosing the inflammatory and scarring components of fatty liver disease that imaging cannot fully capture. But biopsy is invasive, expensive, and subject to sampling error, since a needle samples only a tiny sliver of the organ. For that reason, clinical prediction tools and blood-based biomarkers are used increasingly to identify people at high risk of advanced disease without needing a biopsy.¹⁵

Genetics and Who Is Most Susceptible

Not everyone exposed to the same metabolic risk factors develops fatty liver, and genetics help explain why. The strongest known genetic risk factor is a variant in the PNPLA3 gene. People who carry two copies of the risk allele have liver fat levels more than double those of noncarriers.¹⁶ The variant is most common in Hispanic populations, which partly explains why this group has higher rates of fatty liver disease. The same variant is also linked to greater disease severity, including higher grades of steatosis and more advanced fibrosis, independent of weight or diabetes status.¹⁷

Fatty Liver in People Who Are Not Overweight

One of the most persistent misconceptions about fatty liver is that it only affects people who are visibly overweight. In reality, lean individuals with a normal BMI can and do develop the condition. Globally, lean MASLD is estimated to affect around 13% of the population, with higher rates in Asian populations.¹⁸ A study of normal-weight individuals found that about one in five had fatty liver, and despite their normal BMI, they showed substantial rates of high cholesterol, high blood pressure, and type 2 diabetes. Visceral fat, the deep belly fat that wraps around organs and is not always visible externally, was a strong independent predictor of the condition.¹⁹

Perhaps more concerning, individuals with lean fatty liver face equal or even higher overall mortality rates compared to those with fatty liver who are overweight.¹⁸ This may partly reflect delayed diagnosis. When a thin person has unexplained liver enzyme elevations, fatty liver is often not the first thing considered.

The Heart Connection

Fatty liver is often framed as a liver problem, but the leading cause of death in people with the condition is cardiovascular disease, not liver failure. The association between fatty liver and heart problems is well established and holds even after accounting for the usual risk factors like high cholesterol, diabetes, and obesity. A meta-analysis found that people with fatty liver had roughly 78% higher risk of cardiovascular disease and about double the risk of stroke compared to those without the condition.²⁰ The link extends beyond heart attacks and strokes to include structural heart changes, heart rhythm disturbances, and increased artery plaque buildup.²¹ The increased cardiovascular risk appears to be independent of the traditional risk factors shared between the two conditions.²²

The same meta-analysis also found signals linking fatty liver to higher rates of breast and colorectal cancers, though the data there was more varied.²⁰ The takeaway for patients is that a fatty liver diagnosis should prompt attention to heart health, not just liver monitoring.

Children Get It Too

Fatty liver is not an adults-only problem. It is now the leading cause of chronic liver disease in children, affecting up to an estimated 10% of the general pediatric population and as many as 40% of children with obesity.²³ The disease spectrum in children mirrors that in adults, ranging from simple steatosis to steatohepatitis, fibrosis, and in rare cases cirrhosis. The pattern of liver damage can differ, however: children more often show a portal-predominant pattern of inflammation, while adults tend toward lobular inflammation. This matters because it can affect which noninvasive tools perform best in younger patients and how biopsies are interpreted.

What Helps and What Treatments Exist

Weight loss remains the single most effective intervention for metabolic fatty liver. Losing around 5% of body weight generally improves liver enzyme levels, while losing 7% or more begins to reverse the actual structural changes seen on biopsy.²⁴ How you lose the weight matters less than that you sustain it. Exercise has independent benefits for liver fat reduction even without dramatic changes on the scale, likely through improvements in insulin sensitivity.

For many years, there was no approved medication specifically for fatty liver disease. That changed in 2024 with the approval of resmetirom, the first drug cleared by the FDA for non-cirrhotic MASH with mild to advanced fibrosis. It works by activating a receptor in the liver that ramps up fat burning and reduces new fat production, while limiting effects on the rest of the body.²⁵ In its pivotal trial, about 26–30% of patients on resmetirom achieved resolution of their steatohepatitis without worsening fibrosis after one year, compared to roughly 10% on placebo. About a quarter saw at least one stage of fibrosis improvement.²⁶ The drug also reduces atherogenic lipid levels, which matters given the cardiovascular risks described above.²⁷ GLP-1 receptor agonists, the same class of drugs used for type 2 diabetes and obesity, are also being studied for fatty liver and may eventually complement resmetirom by targeting the metabolic drivers from outside the liver.

The Stigma of the Name “Fatty”

The 2023 nomenclature change was driven partly by science and partly by patient experience. There was genuine concern that the word “fatty” in “fatty liver disease” reinforced shame and blame, particularly in patients already struggling with weight-related stigma. Interestingly, surveys exploring this found a disconnect: while the word “obesity” was perceived as stigmatizing by patients, the medical term “steatotic liver disease” was generally not seen as carrying the same negative weight.²⁸ Whether the new names ultimately help reduce stigma or simply move the discomfort around remains an open question, but the shift toward defining the disease by what it is (metabolic dysfunction with liver fat) rather than what it is not (not caused by alcohol) represents a genuine conceptual improvement in how clinicians communicate with patients about a condition that affects an enormous share of the global population.